Clinical trial · Interventional
Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells
Effect of Annona Muricata Leaves on Nutritional Status, Quality of Life, Fecal Butyrate, Inflammation, and Colorectal Cancer Cells
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Annona muricata L., include the leaves, is found to contain biologically active Annonaceous acetogenins and plant polyphenols that are important components of human diet and a number of them are considered to have chemopreventive and therapeutic properties against cancer. To confirm previous findings in in vitro, animal study and traditionally use, a human, ex vivo and in vitro studies were conducted to evaluate the effects of consecutive ingestion of A. muricata leaves extract for eight weeks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Annona muricata extract | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Annona muricata extract
- description
- Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
- interventionNames
- Dietary Supplement: Annona muricata extract
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Maltose capsule, 300 mg/day, for eight weeks
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- Nutritional Status
- timeFrame
- eight weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with Colorectal Carcinoma * Have undergone standard therapy * Satisfactory haematological or biochemical functions * Karnofsky performance status of ≥ 60% * Willing not to take probiotic supplement during study period Exclusion Criteria: * Uncontrolled hypertension * Serious heart, kidney, liver endocrine or neurologic/psychiatric diseases * Physical and mental disability that renders them unable to verbally communicate * History of recent cancers * Pregnant, lactating, or not using adequate contraception * Patient on other investigational drug
References
Publications (0)
Data not yet available